SFA Therapeutics is developing a first-in-class oral small-molecule platform designed to restore immune balance by re-engaging the body’s own regulatory pathways—aiming for durable disease control without chronic immune suppression. Our lead program targets the large, underserved mild-to-moderate psoriasis market, where we have generated compelling human clinical signals demonstrating strong efficacy and a favorable tolerability profile versus current oral standards of care. Built on a scalable chemistry and manufacturing approach and supported by a growing IP estate, the platform is extensible across autoimmune and inflammatory diseases, with additional programs advancing in MASH and pancreatic cancer based on standout preclinical and early human experience. We are assembling a syndicate to accelerate pivotal development and strategic partnering.